Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Cellectis S.A. is a U.S. business entity operating within the Biological Products, (No Diagnostic Substances) sector (SIC 2836). Publicly traded on the Nasdaq under the ticker symbol CLLS, the company is incorporated in I0. Our proprietary Semantic Risk Score of 34 indicates moderate transparency based on filing patterns, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 2836 classification, Cellectis S.A. serves as a key benchmark for investors and analysts monitoring I0 corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Federal Contracts
IGF::OT::IGF DESIGN, ENGINEERING, AND DELIVERY, OF A CUSTOM TALEN CLEAVING NIH-CRM'S EPISOMAL TARGET SEQUENCE. DESIGN AND GENERATION OF EPISOMAL TARGET SEQUENCE PLASMID, CLONING OF EACH TALAEN UNIT IN YEAST EXPRESSION VECTOR, AND MEASUREMENT OF CLEAVAGE RATE BY YEAST SINGLE STRAND ANNEALING (SSA) ASSAY.
TAS::75 0888::TAS TALEN -ACC-RUO - TALEN ACCESS
IGF::OT::IGF OTHER FUNCTIONS-GENE SEQUENCING SERVICES
IGF::OT::IGF OTHER FUNCTIONS; TALENA SURE KOA : DESIGN, ENGINEERING AND DELIVERY OF A TALENA SURE KOA CLEAVING CUSTOMERS EPISOMAL TARGET SEQUENCE, FOR GENE KNOCKOUT PURPOSES. CATALOG#: TALEN-SKO-RUO
DESIGNING AND ENGINEERING OF TALEN SURE KO CUSTOM REAGENT
IGF::OT::IGF DEVELOP ENZYME SYSTEM
LABORATORY TESTING SERVICES
CUSTOM TALEN
CELLECTIS BIORESEARCH INC.:1196591 [12-006520]
TALEN ACCESS DESIGN, ENGINEERING AND DELIVERY OF A CUSTOM TALEN CLEAVING CUSTOMER S EPISOMAL TARGET SEQUENCE.
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 180 peers in Biological Products, (No Diagnostic Substances) (SIC 2836)
Side-by-side financial showdown — revenue, margins, and growth.
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →